• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Oscar Health Announces Strong Financial Results for Second Quarter 2023

    8/8/23 4:05:00 PM ET
    $OSCR
    Medical Specialities
    Health Care
    Get the next $OSCR alert in real time by email
    • For the quarter ended June 30, 2023:
      • Direct and Assumed Policy Premiums of $1.6 billion, a 3% decrease YoY
      • Premiums earned of $1.5 billion, a 48% increase YoY
      • Medical Loss Ratio of 79.9%, a 230 bps improvement YoY
      • Net loss of ($15.4) million, an improvement of $96.7 million YoY
      • Adjusted EBITDA of $35.6 million, an improvement of $111.4 million YoY
      • InsuranceCo Administrative Expense Ratio of 16.7%, a 280 bps improvement YoY
      • InsuranceCo Combined Ratio of 96.7%, a 500 bps improvement YoY
      • Adjusted Administrative Expense Ratio of 19.5%, a 420 bps improvement YoY

    Health tech company Oscar Health, Inc. (NYSE:OSCR) today announced its financial results for the second quarter ended June 30, 2023.

    "Our strong second quarter results demonstrate that our pricing discipline, renewed operational focus, and solid execution are driving meaningful impact across our business," said Mark Bertolini, CEO of Oscar. "Based on strong year-to-date performance, we now expect to be towards the low-end of our MLR guidance and high-end of our full year Adjusted EBITDA guidance. We remain on track to deliver on our profitability targets and I am pleased with our progress to date."

    Total Direct and Assumed Policy Premiums were $1.6 billion in the quarter, down 3% year-over-year ("YoY"), driven primarily by lower membership, partially offset by rate increases. Premiums earned in the quarter were up 48% YoY, driven primarily by lower risk transfer per member as a percent of premiums, and the impact of deposit accounting for quota share reinsurance agreements.

    Oscar's InsuranceCo Combined Ratio, which is the sum of its Medical Loss Ratio ("MLR") and the InsuranceCo Administrative Expense Ratio, improved 500 bps YoY to 96.7%, reflecting a consolidated profit across the insurance companies, driven by both an improved MLR and administrative cost efficiencies. Specifically, the MLR improved 230 bps YoY to 79.9%, due to a disciplined pricing strategy and total cost of care initiatives. The InsuranceCo Administrative Expense Ratio improved 280 bps YoY to 16.7%, driven primarily by lower distribution expenses.

    The Adjusted Administrative Expense Ratio improved 420 bps YoY to 19.5%, driven primarily by lower distribution expenses, variable expense efficiencies, and higher investment income. Adjusted EBITDA of $35.6 million significantly improved by $111.4 million YoY, and also improved as a percentage of premiums before ceded reinsurance by 8 points as compared to the prior period. Net loss of ($15.4) million improved by $96.7 million YoY, and decreased as a percentage of premiums before ceded reinsurance by 7 points YoY.

    Oscar is reaffirming its full year 2023 outlook across all metrics as provided in its financial results press release dated February 9, 2023, with MLR now projected to be towards the low-end of the 82% - 84% range and Adjusted EBITDA1 projected to be towards the high-end of the ($175) million - ($75) million range, towards a ($75) million loss.

    Effective August 14, 2023, Oscar's current Chief Transformation Officer, R. Scott Blackley, will transition to the role of Chief Financial Officer. Mr. Blackley will oversee treasury, actuarial, financial reporting, capital management and investor relations functions. Oscar's current Chief Financial Officer and Board Member, Sid Sankaran, will step down effective August 13, 2023, and will maintain his position on the Board.

    ______________________________

    1

    See "Non-GAAP Financial Information" below.

    Financial Results Summary

     

     

     

     

     

     

     

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

    (in thousands)

    Premiums before ceded reinsurance

    $

    1,484,538

     

     

    $

    1,368,477

     

     

    $

    2,910,800

     

     

    $

    2,683,541

     

    Reinsurance premiums ceded

     

    (9,572

    )

     

     

    (373,882

    )

     

     

    (7,208

    )

     

     

    (733,545

    )

    Premiums earned

    $

    1,474,966

     

     

    $

    994,595

     

     

    $

    2,903,592

     

     

    $

    1,949,996

     

    Total revenue

    $

    1,521,535

     

     

    $

    1,017,319

     

     

    $

    2,991,220

     

     

    $

    1,990,084

     

    Total operating expenses

    $

    1,528,064

     

     

    $

    1,123,806

     

     

    $

    3,023,114

     

     

    $

    2,165,100

     

    Net loss

    $

    (15,425

    )

     

    $

    (112,125

    )

     

    $

    (55,053

    )

     

    $

    (189,445

    )

    Key Metrics and Non-GAAP Financial Metrics

     

     

     

     

     

     

     

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Direct and Assumed Policy Premiums (in thousands)

    $

    1,645,169

     

     

    $

    1,694,927

     

     

    $

    3,364,578

     

     

    $

    3,376,138

     

    Medical Loss Ratio

     

    79.9

    %

     

     

    82.2

    %

     

     

    78.2

    %

     

     

    79.9

    %

    InsuranceCo Administrative Expense Ratio

     

    16.7

    %

     

     

    19.5

    %

     

     

    17.7

    %

     

     

    19.7

    %

    InsuranceCo Combined Ratio

     

    96.7

    %

     

     

    101.7

    %

     

     

    95.8

    %

     

     

    99.6

    %

    Adjusted Administrative Expense Ratio

     

    19.5

    %

     

     

    23.7

    %

     

     

    20.6

    %

     

     

    23.7

    %

    Adjusted EBITDA(1) (in thousands)

    $

    35,572

     

     

    $

    (75,805

    )

     

    $

    86,640

     

     

    $

    (112,845

    )

    (1)

    Adjusted EBITDA is a non-GAAP measure. See "Key Operating and Non-GAAP Financial Metrics - Adjusted EBITDA" in this release for a reconciliation to net loss, the most directly comparable GAAP measure, and for information regarding Oscar's use of Adjusted EBITDA.

     

     

     

     

     

     

     

    As of June 30,

    Membership by Offering

     

    2023

     

    2022

    Individual and Small Group

     

    900,228

     

    986,017

    Medicare Advantage

     

    1,843

     

    4,658

    Cigna + Oscar(1)

     

    68,472

     

    46,045

    Total Members

     

    970,543

     

    1,036,720

    (1)

    Represents total membership for Oscar's co-branded partnership with Cigna.

    Quarterly Conference Call Details

    Oscar will host a conference call to discuss the financial results today, August 8, 2023, at 5:00 p.m. (ET). A live audio webcast and a supplemental presentation will be available via the Investor Relations page of Oscar's website at ir.hioscar.com. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

    Non-GAAP Financial Information

    This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America ("GAAP"). A reconciliation of the non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release. Oscar has not provided a quantitative reconciliation of forecasted Adjusted EBITDA to forecasted GAAP net loss within this press release because Oscar is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence. These items include, but are not limited to, stock-based compensation expense. These items, which could materially affect the computation of forecasted GAAP net loss, are inherently uncertain and depend on various factors, some of which are outside of Oscar's control. As such, any associated estimate and its impact on GAAP net loss could vary materially. For more information regarding Adjusted EBITDA, please see "Key Operating and Non-GAAP Financial Metrics" below.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about our financial outlook and estimates, including direct and assumed policy premiums, medical loss ratio, administrative expense ratio, Adjusted EBITDA and other financial performance metrics, and the related underlying assumptions, our business and financial prospects, and our management's plans and objectives for future operations, expectations and business strategy. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue" or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control.

    Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our ability to execute our strategy and manage our growth effectively; our ability to retain and expand our member base; heightened competition in the markets in which we participate; our ability to accurately estimate our incurred medical expenses or effectively manage our medical costs or related administrative costs; our ability to achieve or maintain profitability in the future; changes in federal or state laws or regulations, including changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the "ACA") and any regulations enacted thereunder; our ability to comply with ongoing regulatory requirements, including capital reserve and surplus requirements and applicable performance standards; changes or developments in the health insurance markets in the United States, including passage and implementation of a law to create a single-payer or government-run health insurance program; our ability to comply with applicable privacy, security, and data laws, regulations, and standards, including as a result of our participation in government-sponsored programs, such as Medicare; our ability to arrange for the delivery of quality care and maintain good relations with the physicians, hospitals, and other providers within and outside our provider networks; unanticipated results of risk adjustment programs; our ability to utilize quota share reinsurance to reduce our capital and surplus requirements and protect against downside risk on medical claims; unfavorable or otherwise costly outcomes of lawsuits and claims that arise from the extensive laws and regulations to which we are subject; our ability to attract and retain qualified personnel; incurrence of cyber-security breaches of our and our partners' information and technology systems; our ability to remediate a material weakness in our internal controls over financial reporting and the identification of additional material weaknesses in the future or other failure to maintain an effective system of internal controls; adverse publicity or other adverse consequences related to our dual class structure or "controlled company" status; and the other factors set forth under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, filed with the Securities and Exchange Commission ("SEC"), and our other filings with the SEC, including our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, to be filed with the SEC.

    You are cautioned not to place undue reliance on any forward-looking statements made in this press release. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.

    About Oscar Health

    Oscar Health, Inc. ("Oscar") is the first health insurance company built around a full stack technology platform and a relentless focus on serving its members. At Oscar, our mission is to make a healthier life accessible and affordable for all. Headquartered in New York City, Oscar has been challenging the health care system's status quo since our founding in 2012. The company's member-first philosophy and innovative approach to care has earned us the trust of nearly one million members, as of June 30, 2023. We offer Individual & Family, Small Group and Medicare Advantage plans, and +Oscar, our full stack technology platform, to others within the provider and payor space. Our vision is to refactor health care to make good care cost less. Refactor is a term used in software engineering that means to improve the design, structure, and implementation of the software, while preserving its functionality. At Oscar, we take this definition a step further. We improve our members' experience by building trust through deep engagement, personalized guidance, and rapid iteration.

     

    Oscar Health, Inc.

    Consolidated Statements of Operations

    (in thousands, except share and per share amounts)

    (unaudited)

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

    Revenue

     

     

     

     

     

     

     

    Premiums before ceded reinsurance

    $

    1,484,538

     

     

    $

    1,368,477

     

     

    $

    2,910,800

     

     

    $

    2,683,541

     

    Reinsurance premiums ceded

     

    (9,572

    )

     

     

    (373,882

    )

     

     

    (7,208

    )

     

     

    (733,545

    )

    Premiums earned

     

    1,474,966

     

     

     

    994,595

     

     

     

    2,903,592

     

     

     

    1,949,996

     

    Administrative services revenue

     

    3,856

     

     

     

    20,452

     

     

     

    7,741

     

     

     

    38,945

     

    Investment income and other revenue

     

    42,713

     

     

     

    2,272

     

     

     

    79,887

     

     

     

    1,143

     

    Total revenue

     

    1,521,535

     

     

     

    1,017,319

     

     

     

    2,991,220

     

     

     

    1,990,084

     

     

     

     

     

     

     

     

     

    Operating Expenses

     

     

     

     

     

     

     

    Claims incurred, net

     

    1,181,999

     

     

     

    808,639

     

     

     

    2,273,591

     

     

     

    1,543,205

     

    Other insurance costs

     

    197,784

     

     

     

    170,200

     

     

     

    425,215

     

     

     

    335,602

     

    General and administrative expenses

     

    76,453

     

     

     

    80,754

     

     

     

    178,603

     

     

     

    155,418

     

    Federal and state assessments

     

    72,647

     

     

     

    68,749

     

     

     

    146,538

     

     

     

    138,616

     

    Premium deficiency reserve release

     

    (819

    )

     

     

    (4,536

    )

     

     

    (833

    )

     

     

    (7,741

    )

    Total operating expenses

     

    1,528,064

     

     

     

    1,123,806

     

     

     

    3,023,114

     

     

     

    2,165,100

     

    Loss from operations

     

    (6,529

    )

     

     

    (106,487

    )

     

     

    (31,894

    )

     

     

    (175,016

    )

    Interest expense

     

    6,120

     

     

     

    6,141

     

     

     

    12,256

     

     

     

    10,362

     

    Other expenses (income)

     

    1,612

     

     

     

    (793

    )

     

     

    7,718

     

     

     

    2,260

     

    Loss before income taxes

     

    (14,261

    )

     

     

    (111,835

    )

     

     

    (51,868

    )

     

     

    (187,638

    )

    Income tax expense

     

    1,164

     

     

     

    290

     

     

     

    3,185

     

     

     

    1,807

     

    Net loss

     

    (15,425

    )

     

     

    (112,125

    )

     

     

    (55,053

    )

     

     

    (189,445

    )

    Less: Net income (loss) attributable to noncontrolling interests

     

    103

     

     

     

    39

     

     

     

    247

     

     

     

    (2,129

    )

    Net loss attributable to Oscar Health, Inc.

    $

    (15,528

    )

     

    $

    (112,164

    )

     

    $

    (55,300

    )

     

    $

    (187,316

    )

     

     

     

     

     

     

     

     

    Earnings (Loss) per Share

     

     

     

     

     

     

     

    Net loss per share attributable to Oscar Health, Inc., basic and diluted

    $

    (0.07

    )

     

    $

    (0.53

    )

     

    $

    (0.25

    )

     

    $

    (0.89

    )

    Weighted average common shares outstanding, basic and diluted

     

    219,400,458

     

     

     

    211,311,494

     

     

     

    218,163,533

     

     

     

    210,930,686

     

     

    Oscar Health, Inc.

    Consolidated Balance Sheets

    (in thousands, except share and per share amounts)

    (unaudited)

     

     

    June 30, 2023

     

    December 31, 2022

    Assets

     

     

     

    Current Assets:

     

     

     

    Cash and cash equivalents

    $

    2,322,069

     

     

    $

    1,558,595

     

    Short-term investments

     

    1,255,705

     

     

     

    1,397,287

     

    Premiums and accounts receivable

     

    193,079

     

     

     

    216,475

     

    Risk adjustment transfer receivable

     

    60,335

     

     

     

    49,861

     

    Reinsurance recoverable

     

    353,883

     

     

     

    892,887

     

    Other current assets

     

    7,561

     

     

     

    6,450

     

    Total current assets

     

    4,192,632

     

     

     

    4,121,555

     

    Property, equipment, and capitalized software, net

     

    63,053

     

     

     

    59,888

     

    Long-term investments

     

    189,638

     

     

     

    222,919

     

    Restricted deposits

     

    27,292

     

     

     

    27,483

     

    Other assets

     

    92,330

     

     

     

    94,756

     

    Total Assets

    $

    4,564,945

     

     

    $

    4,526,601

     

     

     

     

     

    Liabilities and Stockholders' Equity

     

     

     

    Current Liabilities:

     

     

     

    Benefits payable

    $

    855,711

     

     

    $

    937,727

     

    Risk adjustment transfer payable

     

    1,982,999

     

     

     

    1,517,493

     

    Premium deficiency reserve

     

    3,381

     

     

     

    4,214

     

    Unearned premiums

     

    73,072

     

     

     

    78,998

     

    Accounts payable and other liabilities

     

    261,519

     

     

     

    297,841

     

    Reinsurance payable

     

    67,635

     

     

     

    427,649

     

    Total current liabilities

     

    3,244,317

     

     

     

    3,263,922

     

    Long-term debt

     

    298,388

     

     

     

    297,999

     

    Other liabilities

     

    70,275

     

     

     

    72,280

     

    Total liabilities

     

    3,612,980

     

     

     

    3,634,201

     

    Commitments and contingencies

     

     

     

    Stockholders' Equity

     

     

     

    Preferred stock, $0.00001 par value; 82,500,000 shares authorized, none issued or outstanding as of June 30, 2023 and December 31, 2022

     

    —

     

     

     

    —

     

    Class A common stock, $0.00001 par value; 825,000,000 shares authorized, 186,789,874 and 181,176,239 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively

     

    2

     

     

     

    2

     

    Class B common stock, $0.00001 par value; 82,500,000 shares authorized, 35,115,807 shares issued and outstanding as of June 30, 2023 and December 31, 2022

     

    —

     

     

     

    —

     

    Treasury stock (314,600 shares as of June 30, 2023 and December 31, 2022)

     

    (2,923

    )

     

     

    (2,923

    )

    Additional paid-in capital

     

    3,620,766

     

     

     

    3,509,007

     

    Accumulated deficit

     

    (2,661,287

    )

     

     

    (2,605,987

    )

    Accumulated other comprehensive income (loss)

     

    (6,856

    )

     

     

    (9,715

    )

    Total Oscar Health, Inc. stockholders' equity

     

    949,702

     

     

     

    890,384

     

    Noncontrolling interests

     

    2,263

     

     

     

    2,016

     

    Total stockholders' equity

     

    951,965

     

     

     

    892,400

     

    Total Liabilities and Stockholders' Equity

    $

    4,564,945

     

     

    $

    4,526,601

     

     

    Oscar Health, Inc.

    Consolidated Statements of Cash Flows

    (in thousands) (unaudited)

     

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

    Cash flows from operating activities:

     

     

     

    Net loss

    $

    (55,053

    )

     

    $

    (189,445

    )

    Adjustments to reconcile net loss to net cash provided by operating activities:

     

     

     

    Deferred taxes

     

    26

     

     

     

    4

     

    Net realized loss on sale of financial instruments

     

    9

     

     

     

    508

     

    Depreciation and amortization expense

     

    13,761

     

     

     

    7,490

     

    Amortization of debt issuance costs

     

    389

     

     

     

    324

     

    Stock-based compensation expense

     

    104,773

     

     

     

    54,681

     

    Investment amortization, net of accretion

     

    (15,275

    )

     

     

    3,141

     

    Changes in assets and liabilities:

     

     

     

    (Increase) / decrease in:

     

     

     

    Premiums and accounts receivable

     

    23,396

     

     

     

    (35,835

    )

    Risk adjustment transfer receivable

     

    (10,474

    )

     

     

    (13,859

    )

    Reinsurance recoverable

     

    539,004

     

     

     

    (308,214

    )

    Other assets

     

    1,294

     

     

     

    (16,826

    )

    Increase / (decrease) in:

     

     

     

    Benefits payable

     

    (82,016

    )

     

     

    366,945

     

    Unearned premiums

     

    (5,925

    )

     

     

    (2,353

    )

    Premium deficiency reserve

     

    (832

    )

     

     

    (7,741

    )

    Accounts payable and other liabilities

     

    (38,330

    )

     

     

    (11,125

    )

    Reinsurance payable

     

    (360,015

    )

     

     

    225,687

     

    Risk adjustment transfer payable

     

    465,507

     

     

     

    703,934

     

    Net cash provided by operating activities

     

    580,239

     

     

     

    777,316

     

    Cash flows from investing activities:

     

     

     

    Purchase of investments

     

    (537,688

    )

     

     

    (312,104

    )

    Sale of investments

     

    19,160

     

     

     

    243,400

     

    Maturity of investments

     

    711,453

     

     

     

    261,334

     

    Purchase of property, equipment and capitalized software

     

    (12,996

    )

     

     

    (12,265

    )

    Change in restricted deposits

     

    (522

    )

     

     

    1,023

     

    Net cash provided by investing activities

     

    179,407

     

     

     

    181,388

     

    Cash flows from financing activities:

     

     

     

    Proceeds from long-term debt

     

    —

     

     

     

    305,000

     

    Payments of debt issuance costs

     

    —

     

     

     

    (7,035

    )

    Proceeds from joint venture contribution

     

    471

     

     

     

    1,271

     

    Proceeds from exercise of stock options

     

    2,586

     

     

     

    924

     

    Net cash provided by financing activities

     

    3,057

     

     

     

    300,160

     

    Increase in cash, cash equivalents and restricted cash equivalents

     

    762,703

     

     

     

    1,258,864

     

    Cash, cash equivalents, restricted cash and cash equivalents—beginning of period

     

    1,580,497

     

     

     

    1,125,557

     

    Cash, cash equivalents, restricted cash and cash equivalents—end of period

     

    2,343,200

     

     

     

    2,384,421

     

    Cash and cash equivalents

     

    2,322,069

     

     

     

    2,362,632

     

    Restricted cash and cash equivalents included in restricted deposits

     

    21,131

     

     

     

    21,789

     

    Total cash, cash equivalents and restricted cash and cash equivalents

    $

    2,343,200

     

     

    $

    2,384,421

     

     

    Six Months Ended June 30,

     

     

    2023

     

     

    2022

    Supplemental Disclosures:

     

     

     

    Interest payments

    $

    22,636

     

    $

    9,550

    Income tax payments

    $

    400

     

    $

    1,105

    Key Operating and Non-GAAP Financial Metrics

    We regularly review a number of metrics, including the following key operating and non-GAAP financial metrics, to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, and make strategic decisions. We believe these operational and financial measures are useful in evaluating our performance, in addition to our financial results prepared in accordance with GAAP.

    Members

    Members are defined as any individual covered by a health plan that we offer directly or through a co-branded arrangement. We view the number of members enrolled in our health plans as an important metric to help evaluate and estimate revenue and market share. Additionally, the more members we enroll, the more data we have, which allows us to improve the functionality of our platform.

    Direct and Assumed Policy Premiums

    Direct Policy Premiums are defined as the premiums collected from our members or from the federal government during the period indicated, before risk adjustment and reinsurance. These premiums include APTC, or premium subsidies, which are available to individuals and families with certain annual incomes.

    Assumed Policy Premiums are premiums we receive primarily as part of our reinsurance arrangement under our Cigna+Oscar small group plan offering, and are presented here net of Risk Adjustment for these assumed policies.

    We believe Direct and Assumed Policy Premiums is an important metric to assess the growth of our individual and small group plan offerings going forward. Management also views Direct and Assumed Policy Premiums as a key operating metric because each of our MLR, InsuranceCo Administrative Expense Ratio, InsuranceCo Combined Ratio and Adjusted Administrative Expense Ratio are calculated on the basis of Direct and Assumed Policy Premiums.

    Medical Loss Ratio

    Medical Loss Ratio is calculated as set forth in the table below. Medical claims are total medical expenses incurred by members in order to utilize health care services less any member cost sharing. These services include inpatient, outpatient, pharmacy, and physician costs. Medical claims also include risk sharing arrangements with certain of our providers. The impact of the federal risk adjustment program is included in the denominator of our MLR. We believe MLR is an important metric to demonstrate the ratio of our costs to pay for health care of our members to the premiums before ceded reinsurance. MLRs in our existing products are subject to various federal and state minimum requirements. Below is a calculation of our MLR for the periods indicated.

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

    (in thousands)

    Direct claims incurred before ceded reinsurance (1)

    $

    1,136,687

     

     

    $

    1,092,416

     

     

    $

    2,184,745

     

     

    $

    2,102,451

     

    Assumed reinsurance claims

     

    60,255

     

     

     

    32,555

     

     

     

    107,413

     

     

     

    56,797

     

    Excess of loss ceded claims (2)

     

    (1,474

    )

     

     

    1,509

     

     

     

    (5,620

    )

     

     

    (9,924

    )

    State reinsurance (3)

     

    (10,683

    )

     

     

    (6,946

    )

     

     

    (16,596

    )

     

     

    (18,275

    )

    Net claims before ceded quota share reinsurance (A)

    $

    1,184,785

     

     

    $

    1,119,534

     

     

    $

    2,269,942

     

     

    $

    2,131,049

     

     

     

     

     

     

     

     

     

    Premiums before ceded reinsurance

    $

    1,484,538

     

     

    $

    1,368,477

     

     

    $

    2,910,800

     

     

    $

    2,683,541

     

    Excess of loss reinsurance premiums (4)

     

    (2,233

    )

     

     

    (6,638

    )

     

     

    (6,524

    )

     

     

    (14,766

    )

    Net premiums before ceded quota share reinsurance (B)

    $

    1,482,305

     

     

    $

    1,361,839

     

     

    $

    2,904,276

     

     

    $

    2,668,775

     

    Medical Loss Ratio (A divided by B)

     

    79.9

    %

     

     

    82.2

    %

     

     

    78.2

    %

     

     

    79.9

    %

    (1)

    See the Appendix to this release for a reconciliation of direct claims incurred to claims incurred, net appearing on the face of our statement of operations.

    (2)

    Represents claims ceded to reinsurers pursuant to an excess of loss treaty, for which such reinsurers are financially liable. We use excess of loss reinsurance to limit the losses on individual claims of our members.

    (3)

    Represents payments made by certain state-run reinsurance programs established subject to CMS approval under Section 1332 of the ACA.

    (4)

    Represents excess of loss insurance premiums paid.

    InsuranceCo Administrative Expense Ratio

    InsuranceCo Administrative Expense Ratio is calculated as set forth in the table below. The ratio reflects the costs associated with running our combined insurance companies. We believe InsuranceCo Administrative Expense Ratio is useful to evaluate our ability to manage our expenses as a percentage of premiums before the impact of quota share reinsurance. Expenses necessary to run the insurance company are included in other insurance costs and federal and state assessments. These expenses include variable expenses paid to vendors and distribution partners, premium taxes and healthcare exchange fees, employee-related compensation, benefits, marketing costs, and other administrative expenses. The numerator and denominator in the calculation below reflect an adjustment to remove the impact of the Company's quota share arrangements. Below is a calculation of our InsuranceCo Administrative Expense Ratio for the periods indicated.

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

    (in thousands)

    Other insurance costs

    $

    197,784

     

     

    $

    170,200

     

     

    $

    425,215

     

     

    $

    335,602

     

    Impact of quota share reinsurance (1)

     

    (6,967

    )

     

     

    39,189

     

     

     

    (16,262

    )

     

     

    75,668

     

    Stock-based compensation expense

     

    (14,637

    )

     

     

    (12,411

    )

     

     

    (41,791

    )

     

     

    (25,489

    )

    Federal and state assessment of health insurance subsidiaries

     

    71,913

     

     

     

    68,561

     

     

     

    145,480

     

     

     

    138,772

     

    Health insurance subsidiary adjusted administrative expenses(A)

    $

    248,093

     

     

    $

    265,539

     

     

    $

    512,642

     

     

    $

    524,553

     

     

     

     

     

     

     

     

     

    Premiums before ceded reinsurance

    $

    1,484,538

     

     

    $

    1,368,477

     

     

    $

    2,910,800

     

     

    $

    2,683,541

     

    Excess of loss reinsurance premiums

     

    (2,233

    )

     

     

    (6,638

    )

     

     

    (6,524

    )

     

     

    (14,766

    )

    Net premiums before ceded quota share reinsurance(B)

    $

    1,482,305

     

     

    $

    1,361,839

     

     

    $

    2,904,276

     

     

    $

    2,668,775

     

    InsuranceCo Administrative Expense Ratio(A divided by B)

     

    16.7

    %

     

     

    19.5

    %

     

     

    17.7

    %

     

     

    19.7

    %

    (1)

    Includes ceding commissions received from reinsurers, net of the impact of deposit accounting of $(7,557) and $(1,827) for the three months ended June 30, 2023 and 2022, respectively, and $(15,316) and $(3,659) for the six months ended June 30, 2023 and 2022, respectively.

    InsuranceCo Combined Ratio

    InsuranceCo Combined Ratio is defined as the sum of MLR and InsuranceCo Administrative Expense Ratio. We believe this ratio best represents the core performance of the insurance business, prior to the impact of quota share and net investment income.

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

    2023

     

     

    2022

     

     

    2023

     

     

    2022

     

    Medical Loss Ratio

    79.9

    %

     

    82.2

    %

     

    78.2

    %

     

    79.9

    %

    InsuranceCo Administrative Expense Ratio

    16.7

    %

     

    19.5

    %

     

    17.7

    %

     

    19.7

    %

    InsuranceCo Combined Ratio

    96.7

    %

     

    101.7

    %

     

    95.8

    %

     

    99.6

    %

    Adjusted Administrative Expense Ratio

    The Adjusted Administrative Expense Ratio is an operating ratio that reflects the Company's total administrative expenses ("Total Administrative Expenses"), net of non-cash and non-recurring items (as adjusted, "Adjusted Administrative Expenses"), as a percentage of total revenue, including quota share reinsurance premiums ceded and excluding excess of loss reinsurance premiums ceded and non-recurring items ("Adjusted Total Revenue"). Total Administrative Expenses are calculated as Total Operating Expenses, excluding non-administrative insurance-based expenses and the impact of quota share reinsurance. Adjusted Administrative Expenses are Total Administrative Expenses, net of non-cash and non-recurring expense items. Adjusted Administrative Expenses exclude insurance-based expenses, non-cash expenses and non-recurring expenses. The Company believes Adjusted Administrative Expense Ratio is useful to evaluate the Company's ability to manage its overall administrative expense base. This ratio also provides further clarity into the Company's overall path to profitability. Below is a calculation of our Adjusted Administrative Expense Ratio for the periods indicated.

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

    (in thousands)

    Total Operating Expenses

    $

    1,528,064

     

     

    $

    1,123,806

     

     

    $

    3,023,114

     

     

    $

    2,165,100

     

    Claims incurred, net

     

    (1,181,999

    )

     

     

    (808,639

    )

     

     

    (2,273,591

    )

     

     

    (1,543,205

    )

    Premium deficiency reserve release

     

    819

     

     

     

    4,536

     

     

     

    833

     

     

     

    7,741

     

    Impact of quota share reinsurance (1)

     

    (6,967

    )

     

     

    39,189

     

     

     

    (16,262

    )

     

     

    75,668

     

    Total Administrative Expenses

    $

    339,917

     

     

    $

    358,892

     

     

    $

    734,094

     

     

    $

    705,304

     

    Stock-based compensation expense

     

    (33,279

    )

     

     

    (26,991

    )

     

     

    (104,773

    )

     

     

    (54,681

    )

    Depreciation and amortization

     

    (8,822

    )

     

     

    (3,691

    )

     

     

    (13,761

    )

     

     

    (7,490

    )

    Adjusted Administrative Expenses (A)

    $

    297,816

     

     

    $

    328,210

     

     

    $

    615,560

     

     

    $

    643,133

     

    Total Revenue

    $

    1,521,535

     

     

    $

    1,017,319

     

     

    $

    2,991,220

     

     

    $

    1,990,084

     

    Reinsurance premiums ceded

     

    9,572

     

     

     

    373,882

     

     

     

    7,208

     

     

     

    733,545

     

    Excess of loss reinsurance premiums

     

    (2,233

    )

     

     

    (6,638

    )

     

     

    (6,524

    )

     

     

    (14,766

    )

    Adjusted Total Revenue (B)

    $

    1,528,874

     

     

    $

    1,384,563

     

     

    $

    2,991,904

     

     

    $

    2,708,863

     

    Adjusted Administrative Expense Ratio (A divided by B)

     

    19.5

    %

     

     

    23.7

    %

     

     

    20.6

    %

     

     

    23.7

    %

    (1)

    Includes ceding commissions received from reinsurers, net of the impact of deposit accounting of $(7,557) and $(1,827) for the three months ended June 30, 2023 and 2022, respectively, and $(15,316) and $(3,659) for the six months ended June 30, 2023 and 2022, respectively.

    Adjusted EBITDA

    Adjusted EBITDA is defined as net loss for the Company and its consolidated subsidiaries before interest expense, income tax expense (benefit), depreciation and amortization as further adjusted for stock-based compensation, and other non-recurring items as described below. We present Adjusted EBITDA because we consider it to be an important supplemental measure of our performance and believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Adjusted EBITDA is a non-GAAP measure. Management believes that investors' understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations.

    We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by our competitors, because not all companies and analysts calculate Adjusted EBITDA in the same manner.

    Management uses Adjusted EBITDA:

    • as a measurement of operating performance because it assists us in comparing the operating performance of our business on a consistent basis, as it removes the impact of items not directly resulting from our core operations;
    • for planning purposes, including the preparation of our internal annual operating budget and financial projections;
    • to evaluate the performance and effectiveness of our operational strategies; and
    • to evaluate our capacity to expand our business.

    By providing this non-GAAP financial measure, together with a reconciliation to the most comparable U.S. GAAP measure, we believe we are enhancing investors' understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for net loss or other financial statement data presented in our consolidated financial statements as indicators of financial performance.

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

    (in thousands)

    Net loss

    $

    (15,425

    )

     

    $

    (112,125

    )

     

    $

    (55,053

    )

     

    $

    (189,445

    )

    Interest expense

     

    6,120

     

     

     

    6,141

     

     

     

    12,256

     

     

     

    10,362

     

    Other expenses (income)

     

    1,612

     

     

     

    (793

    )

     

     

    7,718

     

     

     

    2,260

     

    Income tax expense

     

    1,164

     

     

     

    290

     

     

     

    3,185

     

     

     

    1,807

     

    Depreciation and amortization

     

    8,822

     

     

     

    3,691

     

     

     

    13,761

     

     

     

    7,490

     

    Stock-based compensation (1)

     

    33,279

     

     

     

    26,991

     

     

     

    104,773

     

     

     

    54,681

     

    Adjusted EBITDA

    $

    35,572

     

     

    $

    (75,805

    )

     

    $

    86,640

     

     

    $

    (112,845

    )

    (1)

    Represents non-cash expenses related to equity-based compensation programs, which vary from period to period depending on various factors including the timing, number, and the valuation of awards. Includes a non-recurring charge of $46.3 million related to accelerated stock-based compensation expense recognized as a result of the cancellation of the Founders Awards previously granted to Mario Schlosser and Joshua Kushner.

    Appendix

    Reinsurance Impact

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

    (in thousands)

    Quota share ceded premiums

    $

    (5,537

    )

     

    $

    (383,337

    )

     

    $

    6,823

     

     

    $

    (743,265

    )

    Quota share ceded claims

     

    2,787

     

     

     

    310,897

     

     

     

    (3,648

    )

     

     

    587,845

     

    Ceding commission, net of deposit accounting impact (1)

     

    (6,967

    )

     

     

    39,189

     

     

     

    (16,262

    )

     

     

    75,668

     

    Experience refund

     

    (1,801

    )

     

     

    16,093

     

     

     

    (7,506

    )

     

     

    24,486

     

    Net quota share impact

    $

    (11,518

    )

     

    $

    (17,158

    )

     

    $

    (20,593

    )

     

    $

    (55,266

    )

    (1)

    Includes ceding commissions received from reinsurers, net of the impact of deposit accounting of $(7,557) and $(1,827) for the three months ended June 30, 2023 and 2022, respectively, and $(15,316) and $(3,659) for the six months ended June 30, 2023 and 2022, respectively.

    The composition of total reinsurance premiums ceded and reinsurance premiums assumed, which are included as components of total earned premiums in the consolidated statement of operations, is as follows:

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

    (in thousands)

    Reinsurance premiums ceded, gross

    $

    (7,210

    )

     

    $

    (393,857

    )

     

    $

    2,868

     

     

    $

    (760,968

    )

    Experience refunds

     

    (2,362

    )

     

     

    19,975

     

     

     

    (10,076

    )

     

     

    27,423

     

    Reinsurance premiums ceded

     

    (9,572

    )

     

     

    (373,882

    )

     

     

    (7,208

    )

     

     

    (733,545

    )

    Reinsurance premiums assumed

     

    60,395

     

     

     

    34,095

     

     

     

    116,330

     

     

     

    58,885

     

    Total reinsurance premiums (ceded) and assumed

    $

    50,823

     

     

    $

    (339,787

    )

     

    $

    109,122

     

     

    $

    (674,660

    )

    The Company records claims expense net of reinsurance recoveries. The following table reconciles the total claims expense to the net claims expense as presented in the consolidated statement of operations:

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

     

    2022

     

     

    (in thousands)

    Direct claims incurred

    $

    1,136,687

     

     

    $

    1,092,416

     

     

    $

    2,184,745

     

     

    $

    2,102,451

     

    Ceded reinsurance claims

     

    (14,943

    )

     

     

    (316,332

    )

     

     

    (18,567

    )

     

     

    (616,043

    )

    Assumed reinsurance claims

     

    60,255

     

     

     

    32,555

     

     

     

    107,413

     

     

     

    56,797

     

    Total claims incurred, net

    $

    1,181,999

     

     

    $

    808,639

     

     

    $

    2,273,591

     

     

    $

    1,543,205

     

    The Company records general and administrative expenses net of ceding commissions. The following table reconciles total other insurance costs to the amount presented in the consolidated statement of operations:

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2023

     

     

     

    2022

     

     

     

    2023

     

     

    2022

     

     

    (in thousands)

    Other insurance costs, gross

    $

    198,373

     

     

    $

    211,216

     

     

    $

    424,269

     

    $

    414,929

     

    Reinsurance ceding commissions

     

    (589

    )

     

     

    (41,016

    )

     

     

    946

     

     

    (79,327

    )

    Other insurance costs, net

    $

    197,784

     

     

    $

    170,200

     

     

    $

    425,215

     

    $

    335,602

     

    The Company records reinsurance recoverables within current assets on its consolidated balance sheets. The composition of the reinsurance recoverable balance is as follows:

     

     

    June 30, 2023

     

    December 31, 2022

     

     

    (in thousands)

    Ceded reinsurance claim recoverables

     

    $

    344,810

     

    $

    776,266

    Reinsurance ceding commissions

     

     

    2,319

     

     

    42,805

    Experience refunds on reinsurance agreements

     

     

    6,754

     

     

    73,816

    Reinsurance recoverable

     

    $

    353,883

     

    $

    892,887

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230808985886/en/

    Get the next $OSCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSCR

    DatePrice TargetRatingAnalyst
    2/12/2026$18.00Mkt Perform → Outperform
    Raymond James
    1/9/2026$17.00Sell → Neutral
    UBS
    1/5/2026$18.00Underweight → Equal Weight
    Barclays
    12/11/2025$17.00Equal-Weight
    Stephens
    11/26/2025$25.00Neutral → Overweight
    Piper Sandler
    10/14/2025$17.00Neutral
    Goldman
    7/25/2025$14.00Outperform → Neutral
    Robert W. Baird
    7/15/2025$11.00Neutral → Sell
    UBS
    More analyst ratings

    $OSCR
    SEC Filings

    View All

    SEC Form 144 filed by Oscar Health Inc.

    144 - Oscar Health, Inc. (0001568651) (Subject)

    3/2/26 4:17:41 PM ET
    $OSCR
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Oscar Health Inc.

    8-K - Oscar Health, Inc. (0001568651) (Filer)

    3/2/26 6:41:46 AM ET
    $OSCR
    Medical Specialities
    Health Care

    SEC Form S-8 filed by Oscar Health Inc.

    S-8 - Oscar Health, Inc. (0001568651) (Filer)

    2/13/26 4:41:35 PM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thrive Partners Vii Growth Gp, Llc bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    11/22/24 4:33:02 PM ET
    $OSCR
    Medical Specialities
    Health Care

    Co-Founder and Vice Chairman Kushner Joshua bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    11/22/24 4:29:47 PM ET
    $OSCR
    Medical Specialities
    Health Care

    Director Thrive Partners Vii Growth Gp, Llc bought $5,444,343 worth of shares (344,522 units at $15.80) (SEC Form 4)

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    11/18/24 5:02:12 PM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oscar Health Announces Financial Results for Fourth Quarter and Full-Year 2025

    Achieves Record Membership of ~3.4 Million and Provides Full-Year 2026 Outlook Including More Than $18 Billion in Revenue Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR) announced today its financial results for the fourth quarter and full year ended December 31, 2025. "2025 was a reset year for the individual market, and we took decisive actions to return to profitability in 2026," said Mark Bertolini, CEO of Oscar Health. "Our new suite of affordable products, agentic AI features, and exceptional member experience drove record-high membership – positioning us to achieve significantly improved financial performance in 2026. Oscar's growth demonstrates consumers vote where the

    2/10/26 6:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health, Inc. 2025 Fourth Quarter and Full Year Earnings Conference Call

    Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its fourth quarter and full year 2025 financial results before the market opens on Tuesday, February 10, 2026. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following February 10, 2026 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack techno

    1/13/26 6:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Healthcare AI Exits Pilot Phase, Enters Production Deployment

    VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Healthcare organizations are setting the pace for enterprise AI adoption as operational automation moves from experimentation to production scale across hospital systems[1]. The shift reflects a fundamental change in how healthcare leaders view AI technology, with deployment projected to expand the global healthcare AI market from $17.2 billion in 2025 to $77.2 billion by 2035[2]. Five publicly traded companies are positioned at the intersection of this operational transformation, delivering infrastructure that turns AI capabilities into measurable workflow improvements and financial returns

    12/12/25 9:59:27 AM ET
    $CERT
    $CTSH
    $DOCS
    Computer Software: Prepackaged Software
    Technology
    EDP Services
    Medical Specialities

    $OSCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oscar Health upgraded by Raymond James with a new price target

    Raymond James upgraded Oscar Health from Mkt Perform to Outperform and set a new price target of $18.00

    2/12/26 7:19:33 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health upgraded by UBS with a new price target

    UBS upgraded Oscar Health from Sell to Neutral and set a new price target of $17.00

    1/9/26 8:33:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health upgraded by Barclays with a new price target

    Barclays upgraded Oscar Health from Underweight to Equal Weight and set a new price target of $18.00

    1/5/26 8:36:06 AM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, Oscar Insurance Liang Janet was granted 106,458 shares and sold $99,796 worth of shares (7,453 units at $13.39), increasing direct ownership by 57% to 271,532 units (SEC Form 4)

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    3/4/26 4:23:39 PM ET
    $OSCR
    Medical Specialities
    Health Care

    Chief Executive Officer Bertolini Mark T was granted 1,596,877 shares, increasing direct ownership by 56% to 4,463,543 units (SEC Form 4)

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    3/4/26 4:22:11 PM ET
    $OSCR
    Medical Specialities
    Health Care

    Chief Accounting Officer Baltrus Victoria was granted 17,300 shares and sold $62,103 worth of shares (4,638 units at $13.39), increasing direct ownership by 6% to 216,112 units (SEC Form 4)

    4 - Oscar Health, Inc. (0001568651) (Issuer)

    3/4/26 4:19:35 PM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Financials

    Live finance-specific insights

    View All

    Oscar Health Announces Financial Results for Fourth Quarter and Full-Year 2025

    Achieves Record Membership of ~3.4 Million and Provides Full-Year 2026 Outlook Including More Than $18 Billion in Revenue Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR) announced today its financial results for the fourth quarter and full year ended December 31, 2025. "2025 was a reset year for the individual market, and we took decisive actions to return to profitability in 2026," said Mark Bertolini, CEO of Oscar Health. "Our new suite of affordable products, agentic AI features, and exceptional member experience drove record-high membership – positioning us to achieve significantly improved financial performance in 2026. Oscar's growth demonstrates consumers vote where the

    2/10/26 6:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health, Inc. 2025 Fourth Quarter and Full Year Earnings Conference Call

    Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its fourth quarter and full year 2025 financial results before the market opens on Tuesday, February 10, 2026. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following February 10, 2026 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack techno

    1/13/26 6:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health Announces Financial Results for Third Quarter 2025 and Reaffirms 2025 Guidance

    Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR) announced today its financial results for the third quarter ended September 30, 2025, and reaffirmed its full year 2025 outlook, across all metrics, as provided in its preliminary financial results press release dated July 22, 2025. "The individual market is the only source of affordable health coverage for 22 million people who power our economy," said Mark Bertolini, CEO of Oscar Health. "Our market serves the small business, service, and farming sectors, and can meet the healthcare needs of 100 million more working people. Oscar is shaping the future of individual healthcare with affordable, innovative plans and a superior member

    11/6/25 6:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oscar Health Inc.

    SC 13G/A - Oscar Health, Inc. (0001568651) (Subject)

    11/14/24 4:07:27 PM ET
    $OSCR
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Oscar Health Inc.

    SC 13G - Oscar Health, Inc. (0001568651) (Subject)

    11/14/24 1:28:35 PM ET
    $OSCR
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Oscar Health Inc.

    SC 13D/A - Oscar Health, Inc. (0001568651) (Subject)

    11/13/24 9:24:55 PM ET
    $OSCR
    Medical Specialities
    Health Care

    $OSCR
    Leadership Updates

    Live Leadership Updates

    View All

    Oscar Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual

    Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, announced that on January 22, 2024 the Compensation Committee of Oscar's Board of Directors approved the grant of employment inducement restricted stock unit awards covering an aggregate of 104,586 Class A shares of Oscar's common stock to 11 new non-executive employees of Oscar and its affiliates, to induce them to join Oscar and its affiliates. The awards generally vest quarterly over a one-year period following their vesting commencement date, subject to continued employment. The awards were granted under Oscar's 2022 Employment Inducement Award Plan as employment inducement awards pursuant to the New York

    1/26/24 8:00:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health Welcomes Two Healthcare Veterans to its Executive Leadership Team

    Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built around a full stack technology platform, today announced the appointment of two seasoned healthcare executives to round out its leadership bench and further propel its vision to refactor healthcare. Kerry Sain has joined the company as the Executive Vice President of +Oscar, effective August 14, 2023, and Steven Kelmar will join as Executive Vice President and Chief of Staff to the CEO, effective September 21, 2023. In her role, Sain oversees the go-to-market strategy for the +Oscar business and will work closely with Mario Schlosser, President of Technology and Chief Technology Officer, to continue externa

    9/6/23 8:30:00 AM ET
    $OSCR
    Medical Specialities
    Health Care

    Oscar Health, Inc. Appoints Dr. Sean Martin, MD as New Chief Medical Officer

    Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built on a full stack technology platform, today announced that Dr. Sean Martin, MD has been appointed to serve as the company's new Chief Medical Officer, effective immediately. Dr. Martin joined Oscar in 2016 and during his tenure has provided clinical leadership across a number of core clinical functions, including enterprise affordability, medical management, market performance, population health, and behavioral health. In his new role, he will be responsible for implementing Oscar's clinical capabilities and enhancing the quality of care and outcomes for its members. "Dr. Martin is an avid champion of the us

    3/15/23 8:30:00 AM ET
    $OSCR
    Medical Specialities
    Health Care